Is Omnipod® Right For Me?

What life with Omnipod looks like

A look at how Omnipod blends into everyday moments — at home, on the move, and everywhere in between. 

 

Freedom to move

a boy playing with a soccer ball a boy playing with a soccer ball

Tubeless, waterproof design supports everyday life, including personal care, daily routines, and movement at your own pace. 

Stay in the moment

a man wearing a pod is enjoying a meal with a woman a man wearing a pod is enjoying a meal with a woman

Discreet dosing that fits naturally into your day.

Ready for anywhere

woman at the train station with her phone and luggage woman at the train station with her phone and luggage

Wear the Pod for up to three days (72 hours), no matter where life takes you.

‡ The Pod has a waterproof IP28 rating for up to 7.6 metres for 60 minutes. The PDM/Controller is not waterproof.

How tubeless Pods compare to multiple daily injections and tubed pumps

Insulin therapy can be delivered in different ways, but the question you may be asking is: how does life change when you switch to a Pod?  Whether you’re coming from multiple daily injections (MDI) or a traditional tubed pump, here’s a quick, everyday look at how Pods compare to both options. 

 

MDI of 14 syringes versus 1 Pod MDI of 14 syringes versus 1 Pod

Pod vs Multiple Daily Injections (MDI): Simplicity

  • One Pod, up to three days (72 hours), instead of multiple injections every day 
  • Automatically adjusts background insulin every 5 minutes based on your glucose levels, day and night, when paired with a compatible sensor 
  • Discreet and comfortable: a small Pod that sits under clothing 
  • Reduce Stress: Omnipod 5 users stress less about their diabetes1 

 

Pod vs Tubed Pumps: Freedom

  • Completely tubeless, so nothing snags or tangles 
  • Small Pod worn directly on the body 
  • No device to clip on or hide in pockets 
  • Stays out of the way during sleep, sport, work, or everyday life 
young girl jumping out of the water in a swimming pool young girl jumping out of the water in a swimming pool
‡ The Pod has a waterproof IP28 rating for up to 7.6 metres for 60 minutes. The PDM/Controller is not waterproof.

How can you get Omnipod on the NHS?

Many people in the UK access Omnipod through the NHS  Eligibility and pathways can vary by local services.  If you would like to speak to someone that can help you prepare for a discussion on accessing technology with your HCP, the Omnipod Specialists are here to help. 

Our Products

See how our Omnipod systems compare across key features to help you choose what’s right for you. Looking for more information? Visit the Omnipod 5 and Omnipod DASH product pages to learn more. 

 

Omnipod 5 Automated Insulin Delivery (AID) System

Omnipod DASH® Insulin Management System

Tubeless
Waterproof*
Pod worn directly on the body
Dedicated handheld device for bolussing✔ (Controller)✔ (PDM)
Connects with compatible sensors directly 
Automates background insulin based on sensor glucose readings 
Custom Foods feature 
Activity feature 
 Learn moreLearn more

 

Life with Omnipod, made simple

"The three words I would use to describe omnipods are amazing, transformational and freedom." 

 

Ready to take your next step?

Take the first step toward tubeless insulin delivery. Whether you want to try it, see it, or speak with someone about it, we’ll guide you to the option that suits you best. 

‡ The Pod has a waterproof IP28 rating for up to 7.6 metres for 60 minutes. The PDM/Controller is not waterproof.

1. Renard E, et al. Diabetes Care. 2024. doi:10.2337/dc24-1550. A 13-week randomised controlled trial conducted among 194 adults (age 18-70 years) with type 1 diabetes in France and the U.S., comparing the safety and effectiveness of the Omnipod 5 Automated Insulin Delivery (AID) System versus conventional non-AID pump therapy and CGM (control). Mean Type 1 Diabetes Distress Scale (T1- DDS) total score at 13-weeks: Control = 2.08, Omnipod 5 = 1.72. Mean adjusted difference in change in T1-DDS score, Omnipod 5- Control = 0.18, P=0.0094. Mean proportion of participants with clinically meaningful change ≥0.19 (%) at 13-weeks: Control = 45.0%, Omnipod 5 = 53.8%. Mean adjusted difference, Omnipod 5—control = 24.3%, P=0.0145. Study funded by Insulet